IP Library › Granted Patent US 8,551,488
Granted Patent B2
US 8,551,488 · App. 12/803,125 · Granted Oct 8, 2013

Binding molecules for treatment and detection of cancer

Inventors: Cecilia Anna Wilhelmina Geuijen (Moerkapelle, NL); Cornelis Adriaan De Kruif (El de Bilt, NL)
Assignee: Crucell Holland B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,551,488
App. No.
12/803,125
Granted
Oct 8, 2013
Kind
B2
Abstract

Provided are new tumor-associated antigens, binding molecules that specifically bind to the antigens, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The tumor-associated antigens are expressed on cancer cells and binding molecules capable of specifically binding to the antigens can be used in the diagnosis, prevention and/or treatment of cancer.

Claims (16)

1. An isolated binding molecule which binds to an antigen present on acute myeloid leukemia (AML) cells, wherein the binding molecule comprises: a heavy chain variable region comprising SEQ ID NO:3 and a light chain variable region comprising SEQ ID NO: 7.

2. The binding molecule of claim 1 , wherein the binding molecule is human.

3. The binding molecule of claim 2 , wherein the binding molecule is able to specifically bind to leukocyte antigen related receptor protein tyrosine phosphatase.

4. The binding molecule of claim 3 , wherein the binding molecule comprises at least a heavy chain CDR3 region comprising SEQ ID NO:1.

5. The binding molecule of claim 3 , wherein the binding molecule has specific immunoreactivity with acute myeloid leukemia (AML) subtypes M0, M1/2 and M3.

6. The binding molecule of claim 1 , wherein the antigen is leukocyte antigen related receptor protein tyrosine phosphatase.

7. An immunoconjugate comprising the binding molecule of claim 1 , and a tag.

8. A pharmaceutical composition comprising:

the binding molecule of claim 1 , and

a pharmaceutically acceptable carrier.

9. A composition for detecting acute myeloid leukemia (AML), the composition comprising: the binding molecule of claim 3 .

10. A pharmaceutical composition comprising:

the binding molecule of claim 3 , and

a pharmaceutically acceptable carrier.

11. A method for producing the binding molecule of claim 1 , the method comprising: expressing in an isolated host cell a vector comprising a nucleic acid molecule encoding said binding molecule.

12. The method according to claim 11 , wherein the host cell is a human cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2010
From: GEUIJEN, CECILIA A. W.; DE KRUIF, CORNELIS A.
To: CRUCELL HOLLAND B.V.
Reel/Frame 024642/0328 →
Priority Claims (1)
EP 04104999 · Oct 12, 2004 · regional
Continuity (3)
Continuation 11665102
Provisional Application 60618332 · Oct 12, 2004
Related Publication 20100297153A1 · Nov 25, 2010